Efficacy and safety of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone for previously untreated diffuse large B-cell lymphoma: A real-world, multi-center, retrospective cohort study.

Data from a large real-world, retrospective study among patients with untreated DLBCL—presented during the 2025 ASCO Annual Meeting—supports that Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone) is an effective frontline option, with sustained efficacy compared with R-CHOP observed in unselected populations.